Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): Pooled safety analysis of ORIENT 11 and ORIENT 12 studies-MedSci.cn

Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): Pooled safety analysis of ORIENT 11 and ORIENT 12 studies

Gao, G; Zhao, Y; Zhou, J; Li, B; Li, J; Min, F; Zhu, Q; Li, H; Zhou, C; Zhang, L

ANNALS OF ONCOLOGY, 2022; 33 (): S37

科室
- - 订阅+
  - 更多科室
工具
服务